UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934 (Amendment No.    )

Filed by the Registrant [X]

Filed by a Party other than the Registrant [  ]

Check the appropriate box:

[  ]Preliminary Proxy Statement
[  ]Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
[X]Definitive Proxy Statement
[  ]Definitive Additional Materials
[  ]Soliciting Material Pursuant to §240.14a-12

DAXOR CORPORATION

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X]No fee required.
[  ]Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

1)Title of each class of securities to which transaction applies:
2)Aggregate number of securities to which transaction applies:
3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

4)Proposed maximum aggregate value of transaction:
5)Total fee paid:

[  ]Fee paid previously with preliminary materials.

[  ]Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

1)Amount Previously Paid:
2)Form, Schedule or Registration Statement No.:
3)Filing Party:
4)Date Filed:

 

DAXOR CORPORATION

350 FIFTH AVENUE, SUITE 4740109 MECO LANE

NEW YORK, NY 10118OAK RIDGE, TN 37830

 

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD JUNE 27, 201824, 2021

 

NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of DAXOR CORPORATION (the “Company”Company) will be held at the principal officeoffices of the Company, 350 Fifth Avenue (Empire State Building), Suite 4740,Feuer & Orlando, LLP located at 2 Wall Street, 10th Floor, New York, New York 10118,10005, on Wednesday,Thursday, June 27, 201824, 2021 at 10:00 a.m., Eastern Daylight Time,Time. In light of public health concerns regarding COVID-19, if you attend the meeting the Board of Directors requests that you adhere to the following guidelines: 1) If you are not feeling well on the day of the meeting, please do not attend the meeting; 2) Wear a face covering; 3) Practice social distancing and stay 6 feet apart from fellow shareholders while at the meeting. The Annual Meeting is being held for the following purposes, all of which are more particularly described in the accompanying Proxy Statement dated May 18, 2018.June 1, 2021:

 

1.To elect a board of six directors, each to serve for a term of one year or until histheir successor shall have been duly elected and qualified.qualified;
2.To ratify the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the Company for the year ending December 31, 2018.2021; and
 3.Advisory vote on executive compensation.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.

Our Board of Directors recommends a vote “FOR ALL NOMINEES” in Proposal 1, and “FOR” ratification of the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm in Proposal 2.

 

By OrderHolders of record of our common stock at the Boardclose of Directors,business on May 17, 2021 are entitled to notice of and to vote at the meeting and any adjournments or postponements thereof. Shareholders are entitled to one vote per share.

 

ByOrder of the Board of Directors,
/s/ Robert J. Michel
Robert J. Michel
Corporate Secretary

 

Diane M. Meegan

Corporate Secretary

May 22, 2018June 1, 2021

 

IF YOU DO NOT EXPECT TO BE PRESENT AT THE MEETING AND WISH YOUR SHARES TO BE VOTED, PLEASE SIGN, DATE AND MAIL THE ACCOMPANYING FORM OF PROXY AS PROMPTLY AS POSSIBLE IN THE ENCLOSED ENVELOPE.Whether or not you plan to attend the Annual Meeting in person, we urge you to vote and submit your proxy in advance of the meeting by one of the methods described in the proxy materials for the Annual Meeting.

 

Important Notice Regarding the Availability of Proxy Materials for the

Stockholder Meeting to be held on Thursday, June 27, 201824, 2021

 

This Proxy Statement and copies of the Company’s most recent Annual Report on Form N-CSR to stockholders are available, without charge, to a shareholderstockholder upon request by contacting John WilkensCalling (888) 774-3268 or writing Robert J. Michel at 350 Fifth Avenue (Empire State Building), Suite 4740, New York, New York 10118109 Meco Lane, Oak Ridge, TN 37830, or at www.Daxor.com.

 

 

 

TABLE OF CONTENTS

 

  PAGE
   
ABOUT THE MEETING1
 
 What is the purpose of the Annual Meeting?1
 Who is entitled to vote?1
 What constitutes a quorum?1
 How do I vote?1
 Can I change my vote after I submit my proxy card?1
 What are the Board’s recommendations?1
 What is our policy with respect to Board member attendance at the Annual Meeting?1
   
COMMON STOCK AND EQUITY OWNERSHIP OF DIRECTORS2
   
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE2
ITEMPROPOSAL 1- ELECTION OF THE BOARD OF DIRECTORS2
   
 Directors and Officers2 - 4
 Board Leadership Structure4
 Audit Committee4
 Board’s Risk Oversight Role4
 Qualifications of the Directors5
 Board Compensation5-65
 Required Vote6
 Recommendation6
   
ITEMPROPOSAL 2- RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM6
   
Report of Audit Committee76
 Fees Paid to WithumSmith+Brown, PC7 - 8
 Required Vote87
 Recommendation87
   
Item 3-ADVISORY VOTE ON THE COMPENSATION LEVELS OF THE COMPANY’S NAMED EXECUTIVESOTHER BUSINESS TO COME BEFORE MEETING87
   
Executive Compensation PolicyCONTROL PERSONS8 - 9
Recommendation9
Other Business to Come Before Meeting9
Control Persons10
   
ADDITIONAL INFORMATION9
   
 Stockholder Proposals for the 20192022 Annual Meeting119
 Administrator and Principal Underwriters119
 Cost and Methods of Solicitation of Proxies119
Householding9
 Submission of Other Communications to the Board1110

 

 

 

PROXY STATEMENT

DAXOR CORPORATION

350 Fifth Avenue, Suite 4740109 Meco Lane

New York, NY 10118Oak Ridge, TN 37830

 

The accompanying proxy is solicited by and on behalf of Daxor Corporation’s (the “Company”Company) Board of Directors (the “Board”Board) for use at our Annual Meeting of Stockholders to be held at our principal office, 350 Fifth Avenue, Suite 4740,the offices of Feuer & Orlando LLP, located at 2 Wall Street, 10th Floor, New York, City, New York 10118,10005, on Wednesday,Thursday, June 27, 201824, 2021 at 10:00 a.m., Eastern Daylight Time,AM EDT, or any adjournment or postponement thereof (“Annual Meeting”Meeting). In light of public health concerns regarding COVID-19, if you attend the meeting the Board of Directors requests that you adhere to the following guidelines: 1) If you are not feeling well on the day of the meeting, please do not attend the meeting; 2) Wear a face covering; and 3) Practice social distancing and stay 6 feet apart from fellow shareholders while at the meeting. Stockholders of record at the close of business on May 4, 201817, 2021 will be entitled to vote at the meeting. The mailing of the Notice of Annual Meeting of Stockholders, this Proxy Statement and the accompanying proxy card will take place on or about May 22, 2018.June 1, 2021.

 

ABOUT THE MEETING

 

What is the purpose of the Annual Meeting?

At our Annual Meeting, stockholders will act upon the matters outlined in the accompanying notice of meeting, including the election of directors. In addition, our management will report on our performance during 20172020 and respond to questions from the stockholders.

 

Who is entitled to vote?

Only stockholders of record at the close of business on the record date, May 4, 2018,17, 2021, are entitled to receive notice of the Annual Meeting and to vote the shares of common stock that they held on that date at the Annual Meeting, or at any time and date to which the Annual Meeting may be properly adjourned or postponed. Each outstanding share entitles its holder to cast one vote on each matter to be voted upon.

 

What constitutes a quorum?

 

The presence at the Annual Meeting, in person or by proxy, of the holders of a majority of the shares of common stock outstanding on the record date will constitute a quorum, permitting the meeting to conduct its business. As of the record date, May 4, 2018, 3,728,71917, 2021, 4,033,877 shares of our common stock were outstanding. Proxies received but marked as abstentions and broker non-votes will be included in the calculation of the number of shares considered to be present at the Annual Meeting.

 

How do I vote?

 

We will solicit proxies by mail. Arrangements will be made with brokerage houses and other custodians, nominees, and fiduciaries to forward solicitation material to the beneficial owners of the shares held of record by such persons, and we will reimburse them for the reasonable out-of-pocket expenses incurred by them in doing so.

 

Shareholders that wish to cast their votes should do so in advance of the meeting via the proxy instruction provided in their mailing. Alternatively, proxy cards with valid control numbers may be hand-delivered in person at the meeting or scanned and e-mailed prior to vote closing at the start of the meeting to Robert J. Michel at rmichel@daxor.com.

Can I change my vote after I submit my proxy card?

The shares represented by the accompanying proxy will be voted as directed with respect to the election of directors, or, if no direction is indicated, will be voted in favor of election as directors of all of the nominees listed below. The shares will be voted as directed with respect to the ratification of the independent registered public accounting firm, or, if no direction is indicated, will be voted in favor orof ratification. Each proxy executed and returned by a stockholder may be revoked at any time hereafter by giving written notice of such revocation to our Corporate Secretary, except as to any matter or matters upon which, prior to such revocation, a vote shall have been cast pursuant to the authority conferred by such proxy.

What are the Board’s recommendations?

Unless you give other instructions on your proxy card, the persons named as proxy holders on the proxy card will vote in accordance with the recommendation of the Board of Directors.Board. The Board’s recommendation is set forth together with the description of each item in this proxy statement. In summary, the Board recommends a vote for election of the nominated slate of directors and for the ratification of the independent registered public accounting firm.

Our Board of Directors, on the recommendation of its audit committee consisting of a majority of independent directors, has selected the firm, of WithumSmith+Brown, PC Certified Public Accountants, as the principal accountants for the current fiscal year. They have served in such capacity since 2016. The audit committee continues to recommend a vote for WithumSmith+Brown, PC to serve as our independent auditors.PC.

 

What is our policy with respect to Board member attendance at the Annual Meeting?

 

Board members are encouraged to attend the Annual Meeting. However, in light of public health concerns regarding the COVID-19 outbreak, Board members may attend this Annual Meeting via teleconference.

1

COMMON STOCK AND EQUITY OWNERSHIP OF DIRECTORS

 

On May 4, 2018,17, 2021, we had issued and outstanding 3,728,7194,033,877 shares of common stock, par value $.01$0.01 per share, each of which entitled the holder to one vote. Voting is not cumulative.

 

As of the record date, the dollar range of shares of the Company beneficially owned by the Estate of Joseph Feldschuh is over $100,000. As of the record date, the dollar range of shares of the Company beneficially owned by Bernhard SaxeJoy Goudie is $1-$0-$10,000. As of the record date, the dollar range of shares of the Company beneficially owned by James Lombard is $10,001-$50,001-$50,000. As of the record date, the dollar range of shares of the Company beneficially owned by Martin S. Wolpoff is $10,001-$50,000.100,000. As of the record date, the dollar range of shares of the Company beneficially owned by Edward Feuer is $1-$10,001-$10, 000.50,000. As of the record date, the dollar range of shares of the Company beneficially owned by Michael Feldschuh is over $100,000. As of the record date, the dollar range of shares of the companyCompany beneficially owned by Jonathan Feldschuh is over $100,000. As of the record date, the dollar range of shares of the Company beneficially owned by Henry D. Cremisi is over $100,000.

 

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Securities Exchange Act of 1934 requires our officers, directors and persons who beneficially own more than ten percent of our common stock to file reports concerning the ownership of our equity securities with the Securities and Exchange Commission and us. Based solely on a review of the copies of such forms furnished to us, we believe that all reports required by Section 16(a) to be filed by our insiders were filed on a timely basis.

ItemPROPOSAL 1. Election of the Board of DirectorsELECTION OF THE BOARD OF DIRECTORS

 

Stockholders are being asked to elect six directors to serve on our Board, of Directors, to hold office until the next annual meeting or until their successors shall have been duly elected and shall have qualified. The proxies will vote all proxies received “FOR” the election as directors of the nominees listed below if no direction to the contrary is given. In the event that any nominee is unable to serve, the proxy solicited herewith may be voted, at the discretion of the management, for the election of another person in his stead. The Board of Directors knows of no reason to anticipate that this will occur.

 

Directors and Officers

 

The management of the Company is the responsibility of the Board of Directors.Board. None of the directors who are not “interested persons” of the Company (as defined in the Investment Company Act of 1940) has ever been an employee of, or consultant to, the Company or its affiliates. Our officers serve annual terms and are elected on an annual basis.

 

The Board of Directors has an audit committee. The Board does not have a standing compensation committee or a nominating committee or a charter with respect to the process for nominating directors for election to our Board of Directors.Board. We qualify as a “controlled company” under NYSE MKTAmerican rules, as the Estate of Joseph Feldschuh, M.D. controls more than 50% of the Company’s voting power, as evidenced by the company’sCompany’s ownership records. As a result, the NYSE MKTAmerican continued listing standards do not require us to have a nominating committee, compensation and stock option committee, or a written charter. In light of our status as a controlled company, our Board determined not to have an independent nominating function, and chose to have the full Board be directly responsible for nominating members of our Board, and not to have a compensation committee.committee, but have the full Board participate directly in consideration of compensation. Accordingly, should the interests of our controlling stockholder differ from those of other stockholders, the other stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance rules for the NYSE MKT.American.

The Company will consider nominees recommended in writing by a stockholder (other than stockholder recommendations of himself or herself) to serve as Directors. The recommendation must contain: (i) the name, address and telephone number of, and number of shares owned by, the stockholder (or group of stockholders), and the related account name, number and broker or account provider name; and (ii) if any such stockholder was not a record owner of the shares at the time the recommendation was submitted, verification acceptable in form and substance to the Company of the stockholder’s ownership of shares at the time the recommendation was made. Stockholders and members of our Board can submit nominees for election to our Board of Directors to Michael Feldschuh for his consideration by February 1, 2022 at 350 Fifth Avenue, Suite 4740, New York, New York 10118.109 Meco Lane, Oak Ridge, TN 37830.

2

 

The names and business addresses of our nominees, their principal occupations and other affiliations during the past five years, the number of portfolios each oversees and other directorships they hold, or have held during the past five years, are set forth below. Michael Feldschuh is an “interested person” of the Company because he is the President and Chief Executive Officer of Daxor. Jonathan Feldschuh is an “interested person” because he is the Chief Scientific Officer. There is no “Fund Complex” as defined in the Investment Company Act of 1940.

 

There are no contracts, arrangements or understandings between any director and any other person (other than the directors acting solely in such capacity) pursuant to which the director has been or is to be selected as a director.

Name, Address3

and Age 

 

Position(s) Held with Company 

Term of Office and Length of Time Served 

Principal Occupation(s) During Past Five Years 

Number of Portfolios Overseen by Director 

Other Directorships Held (during past five years) by Director 

“Noninterested Persons”   

James Lombard
350 Fifth Avenue (Empire State Building), Suite 4740 New York, New York 1018


Age: 83

  DirectorNumber of Other Directorships
PortfoliosHeld (during past
Name, AddressPosition(s) HeldTerm of Office andPrincipal Occupation(s)Overseen byfive years) by
and Agewith CompanyLength of Time ServedDuring Past Five YearsDirectorDirector
“Noninterested Persons”
James LombardDirector One year term, Director since 1989 Director of Administrative Services Division, New York City Council (Retired).
 None None

Martin S. Wolpoff
350 Fifth Avenue (Empire State Building), Suite 4740 New York, New York 1018


Age: 75


109 Meco Lane
  Directorsince 1989 Services Division, New
Oak Ridge, TN 37830York City Council
(Retired).
Age: 86
Henry D. Cremisi, MD FACPDirector One year term, Director since 1989 Educational Consultant,Medical Director, Administration Community School District (Retired).
 None None

Edward Feuer
350 Fifth Avenue (Empire State Building), Suite 4740 New York, New York 1018


Age: 62


109 Meco Lane
  Directorsince 2020 AstraZeneca, a
Oak Ridge, TN 37830Pharmaceutical company 
Age: 63
Edward FeuerDirector One year term, Director since 2016 Managing Partner, Feuer & Orlando
 None None

Bernhard Saxe, Esq.
350 Fifth Avenue (Empire State Building), Suite 4740 New York, New York 1018


Age: 83


109 Meco Lane
  Directorsince 2016 & Orlando, LLP, an
Oak Ridge, TN 37830accounting firm 
Age: 65
Joy Goudie, Esq.Director One year term, Director since 2008 Partner, Foley & Lardner LLP (Retired 2/04), Registered Patent Attorney. None None

Name, Address

and Age 

Position(s) Held with Company 

109 Meco Lane
  

Term of Office and Length of Time Served 

since 2020 

Principal Occupation(s) During Past Five Years 

Number of Portfolios Overseen by Director 

Attorney
  Other Directorships Held (during past five years) by Director 
“Interested Persons”Oak Ridge, TN 37830    

Michael Feldschuh
350 Fifth Avenue (Empire State Building), Suite 4740 New York, New York 10118


Age: 48

  Director 
Age: 64

Number ofOther Directorships
PortfoliosHeld (during past
Name, AddressPosition(s) HeldTerm of Office andPrincipal Occupation(s)Overseen byfive years) by
and Agewith CompanyLength of Time ServedDuring Past Five YearsDirectorDirector
“Interested Persons”
Michael FeldschuhDirector One year term, DirectorExecutive Vice PresidentOneNone
109 Meco Lanesince 2013 

Executive Vice President Chairman, President, CEO

One    None

Jonathan Feldschuh
350 Fifth Avenue (Empire
State Building), Suite 4740,
New York, New York
10118


Age 53

Oak Ridge, TN 37830
  Director 
Age: 51
Jonathan FeldschuhDirector One year term, Director since 2017 Chief Scientific Officer None None
109 Meco Lane   Nonesince 2017
Oak Ridge, TN 37830
Age 56 

 

Board Leadership Structure

 

The Board of Directors is currently comprised of six members, four of whom are independent or disinterested persons, which means that they are not “interested persons” of the Company as defined in Section 2(a)(19) of the Investment Company Act of 1940. If the nominees are elected, the Board will be comprised of six members, four of whom will be independent directors. The Board has general oversight responsibility with respect to the operation of the Company, and has established an audit committee to assist the Board in performing its oversight responsibilities.

 

As Chairman of the Board, Michael Feldschuh is the presiding officer at all meetings of the Board of Directors. We do not have a lead independent director. We have determined that our leadership structure is appropriate given the size and structure of the Company.

 

Audit Committee

 

The audit committee operates pursuant to a Charter approved by the Board of Directors, a copy of which is available on our website. The Charter sets forth the responsibilities of the audit committee. The functions of the audit committee include, among others, to meet with the independent registered public accounting firm of the Company to review the scope of the Company’s audit, the Company’s financial statements and internal accounting controls, and to meet with management concerning these matters, internal audit activities and other matters. The audit committee currently consists of Edward Feuer, James Lombard and Martin Wolpoff,Joy Goudie, all of whom are considered independent under the rules promulgated by The NYSE MKTAmerican and, in addition, are not “interested persons” of the Company as defined in Section 2(a)(19) of the Investment Company Act.Act of 1940. Edward Feuer serves as Chairperson of the audit committee and has been designated as the audit committee Chairperson of the audit committee and has been designated as the audit committee financial expert under the Sarbanes-Oxley Act. There were no items brought before theThe Audit Committee met 4 times in 2017.2020. Please see “Item“Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm” for a discussion regarding the audit committee’s report.

 

Board’s Risk Oversight Role

 

The day-to-day management of various risks relating to our administration and operation is the responsibility of management and other service providers retained by the Board of Directors or by management, most of whom employ professional personnel who have risk management responsibilities. The Board of Directors oversees this risk management function consistent with and as part of its oversight duties. The Board of Directors performs this risk management oversight function directly and, with respect to various matters, through its committees. The Board of Directors has been advisednotes that it is not practicable or possible to identify all of the risks that may impact the Company or to develop procedures or controls that are designed to eliminate all such risk exposures, and that applicable securities law regulations do not contemplate that all such risks be identified and addressed.addressed, but that the Board carefully evaluate and address all material risks.

4

The Board of Directors has overseen our development and administration of a compliance program that meets the requirements of Rule 38a-1 promulgated under the Investment Company Act of 1940, and the development and administration of a code of ethics program that meets the requirements of Rule 17j-1 promulgated under the Investment Company Act of 1940. The Board meets regularly with our Chief Compliance Officer on all aspects of our compliance requirements.

 

Qualifications of the Directors

 

Michael Feldschuh, Jonathan Feldschuh, Edward Feuer, Bernhard Saxe,Henry Cremisi, James Lombard and Martin WolpoffJoy Goudie each take a conservative and thoughtful approach to addressing issues facing the Company. Information indicating certain of the specific experience and qualifications of each of these directors relevant to the Board’s belief that they should serve in this capacity is provided in the table above. This combination of skills and attributes led to the conclusion that each of Messrs. Michael Feldschuh, Jonathan Feldschuh, Edward Feuer, James Lombard, Bernhard Saxe,Joy Goudie, Esq., and Martin WolpoffHenry Cremisi, MD, FACP should serve as a director.

 

In making independent determinations, the Board observes all criteria for independence established by the Securities and Exchange Commission,SEC, The NYSE MKT,American, and other governing laws and regulations. The Board has determined that each of the directors (other than Michael Feldschuh and Jonathan Feldschuh) (i) is “independent” within the definitions contained in the current The NYSE MKTAmerican listing standards and our Corporate Governance Guidelines; and has no other “material relationship” with the Company that could interfere with his ability to exercise independent judgment. The Board has determined that Edward Feuer qualifies as an “audit committee financial expert” as defined by the Securities and Exchange Commission.SEC. In addition, the Board has determined that each member of the audit committee meets the additional independence standards for audit committee members.

 

Board Compensation

 

In June 2017,2020 the outside directors who attended the virtual annual meeting were paid $1,000 each for attendance at the annual meeting and a Board meeting which took place on the same day. EveryThe number of directors who attended the annual meeting was 6. In addition, every director who attended thea dial-in Board meeting was paid $375 for each Board meeting which took place respectively in March,May, September and December 2017.

The2020. Each incumbent director attended at least 75% of the aggregate number of meetings, the total number of Board meetings being 4, of the Board during 2020. Other than the officers identified below, Messrs. Michael Feldschuh, Jonathan Feldschuh and Robert J. Michel, there are no officers of the Company that had aggregate compensation paid to current and former directors in 2017 is set forth inexcess of $120,000 during the following table. There is no “Fund Complex” as defined in the Investment Company Act of 1940.most recently completed fiscal year.

 

Name of Person, Position 

Aggregate

Compensation

From Company

  

Pension or

Retirement Benefits

Accrued As Part of

Company Expenses

 

Annual Benefits

Upon Retirement

 

Total Compensation

Paid

to Director

 
Interested Persons:            
             
Michael Feldschuh, Director $100,000  None None $100,000 
             
Jonathan Feldschuh, Director
 $127,920  None None $127,920 
             
Noninterested Persons:            
             
James Lombard,
Director
 $2,125  None None $2,125 
             
Martin S. Wolpoff, Director
 $2,125  None None $2,125 
             
Edward Feuer,
Director
 $1,750  None None $1,750 
             
Bernhard Saxe, Esq., Director $2,125  None None $2,125 
             
5

     Pension or     
  Aggregate  Retirement Benefits Estimated Annual   
  Compensation  Accrued As Part of Benefits Total Compensation 
Name of Person, Position From Company  Company Expenses Upon Retirement Paid From Company 
Interested Persons:            
             
Michael Feldschuh,            
Director $100,000  None None $100,000 
             
Jonathan Feldschuh,            
Director $127,920  None None $127,920 
             
Noninterested Persons:            
             
James Lombard,            
Director $2,125  None None $2,125 
             
Henry Cremisi,MD            
Director $1,750  None None $1,750 
             
Edward Feuer,            
Director $2,125  None None $2,125 
             
Joy Goudie, Esq.,            
Director $750  None None $750 

Required Vote

Stockholders elect directors by a plurality of the votes cast by shares which are entitled to vote in the election, assuming a quorum is present. For this purpose, “plurality” means that the nominees receiving the largest number of votes from the stockholders will be elected as directors. Abstentions and broker non-votes (if any) will be counted as votes present for purposes of determining whether a quorum is present. Assuming a quorum is present, any shares that do not vote, whether by abstention, broker non-vote or otherwise, will not affect the election of directors.

 

Recommendation

 

The Board of Directors recommends that the stockholders voteFORthe election of the nominees to serve as directors.Shares represented by executed but unmarked proxies will be voted FOR the election of all of the nominees.

 

6

ITEMPROPOSAL 2: RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC

ACCOUNTING FIRM

 

The audit committee selected WithumSmith+Brown, PC as an independent registered public accounting firm, to audit our consolidated financial statements for the year ending December 31, 2018,2020, and requests that the stockholders ratify such selection. If stockholders do not ratify the selection of WithumSmith+Brown, PC, the audit committee will reconsider the selection.

 

If you submit a proxy to us, it will be voted as you direct.If, however, you submit a proxy without specifying voting directions, it will be voted in favor of ratifying WithumSmith+Brown, PC as our independent registered public accounting firm.If your shares are held in “street name” by your broker, nominee, fiduciary or other custodian, your broker, nominee, fiduciary or other custodian may choose to vote for you on the ratification of the appointment of WithumSmith+Brown, PC as independent registered public accountants for the Company, even if you do not provide voting instructions to such nominee.

 

Representatives of WithumSmith+Brown, PC are not expected to be present at the Annual Meeting.

 

Report of Audit Committee

 

The committee submits the following report pursuant to SEC rules:

 

·The committee has reviewed and discussed with management and with WithumSmith+Brown, PC the audited financial statements of the Company for the year ended December 31, 20172020 (the “Financial Statements”Financial Statements).
·
Has advised the management of the Company and the committee that it has discussed with them all the matters required to be discussed by Statement of Auditing Standards No. 114, which include among other items, matters related to the conduct of the audit of the Financial Statements.
·
The committee has received the written disclosures and the letter required by PCOABPCAOB Rule 3526, “Communication with Audit Committees Concerning Independence” (which relates to the auditor’s independence from the Company and its related entities) from WithumSmith+Brown, PC. It has discussed WithumSmith+Brown, PC’s independence with them.

6

·Based upon the aforementioned review, discussions and representations of WithumSmith+Brown, PC and the unqualified audit opinion presented by WithumSmith+Brown, PC on the Financial Statements, the committee recommended to the Board of Directors that the Financial Statements be included in the Company’s Annual Report on Form N-CSR, and that WithumSmith+Brown, PC be selected as the independent registered public accounting firm for the Company for the year ending December 31, 2018.2021.

 

Members of the Audit Committee:

 

Edward Feuer, Chair

James Lombard

Martin S. WolpoffJoy Goudie, Esq.

 

Fees Paid to WithumSmith+Brown, PC

We have engaged WithumSmith+Brown, PC to perform audit services, audit-related services, tax services and other services during the past fiscal year as of December 31, 2017.2020. “Audit services” refer to performing an audit of the registrant’s annual financial statements or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years. “Audit-related services” refer to the assurance and related services by the principal accountant that are reasonably related to the performance of the audit. “Tax services” refer to professional services rendered by the principal accountant for tax compliance, tax advice, and tax planning. The following table details the aggregate fees billed or expected to be billed for past two fiscal years for audit fees, audit-related fees, tax fees and othertax fees by the principal accountant.

  2017  2016 
Audit Fees $55,000  $97,902 
Audit Related  20,000   23,000 
Tax Fees  15,500   19,500 
All Other Fees  0   0 
Total Fees $90,500  $140,402 

  2020  2019 
Audit Fees $82,146  $81,500 
Audit Related Fees  3,947   8,000 
Tax Fees  20,000   20,250 
         
Total Fees $106,093  $109,935 

 

The audit committee has adopted pre-approval policies and procedures that require the audit committee to pre-approve all audit and non-audit services of the registrant, including services provided to any entity affiliated with us.

 

For the past two fiscal years, WithumSmith+Brown, PC did not bill any fees applicable to non-audit services, pursuant to a waiver of the pre-approval requirement.

 

All of the principal accountant’s hours spent on auditing our financial statements were attributed to work performed by full-time permanent employees of the principal accountant.

 

We do not have an investment advisor.

 

Required Vote

 

Assuming a quorum is present at our Annual Meeting, ratification of WithumSmith+Brown, PC will be determined by majority vote. A majority vote will occur if the number of votes cast in favor of ratification exceeds the number of votes cast in opposition to ratification. Assuming a quorum is present; shares not voted at the Annual Meeting will not affect the outcome of the ratification of WithumSmith+Brown, PC.

 

Recommendation

 

The Board recommends that the stockholders voteFORthe ratification of the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the Company for the year ending December 31, 2018.2021. Shares represented by executed but unmarked proxies will be voted FOR ratification of WithumSmith+Brown, PC.

ITEM 3:ADVISORY VOTE ON THE COMPENSATION LEVELS OF THE COMPANY’S NAMED EXECUTIVES

In accordance with Section 14A of the Exchange Act and related rules of the Securities and Exchange Commission, we are providing our shareholders with the opportunity to cast an advisory vote on the compensation of our named executive officers at the 2018 Annual Meeting of Shareholders. This item, commonly referred to as a “say-on-pay” vote, provides you, as a Daxor Corporation shareholder, the opportunity to express your views regarding the compensation to our named executive officers as disclosed in this proxy statement.

The objective of our executive compensation program is to enable us to recruit and retain highly qualified executive talent by providing market-based levels of compensation. We have structured our compensation program to motivate our executives to achieve individual and business performance objectives by varying the compensation in accordance with the success of our business. Highlights of our executive compensation program include the following:

Market-Based Compensation Targets. We generally target the market median (50th percentile) for each major element of compensation for our named executive officers (NEO). In establishing individual incentive targets and awards, we consider the level and nature of the executive’s responsibility, the executive’s experience and the qualitative assessment of the executive’s performance.

Pay for Performance. We believe that a substantial portion of the compensation for our NEO should be “at risk”; meaning that the executive will receive a certain percentage of their total compensation only to the extent Daxor Corporation and the particular executive accomplish goals established. While compensation targets will to a large extent reflect the market, actual compensation in a given year will be based on Daxor Corporation’s performance, and to a lesser extent, on qualitative appraisals of individual performance.

2017 Compensation. Daxor Corporation’s Board does not have a standing compensation committee. Under NYSE MKT rules, Daxor qualifies as a “controlled company” as the Estate of Joseph Feldschuh, M.D. controls more than 50% of the Company’s voting power. As such, the Board has decided not to have a separate compensation committee but to manage executive compensation for named executives as a whole. In 2017 the only NEO was Michael Feldschuh, President and Chairman of the Board. Mr. Feldschuh has elected to reduce his base compensation to below the median market rate and to receive beneficial ownership in the Company in the form of Stock Options. In 2017 Mr. Feldschuh was granted 25,000 options.

Recommendation

The Board recommends that the stockholders voteFORthe advisory vote on the compensation levels of the Company’s named executives.Shares represented by executed but unmarked proxies will be voted FOR the advisory vote on the compensation levels of the Company’s named executives.

 

OTHER BUSINESS TO COME BEFORE THE MEETING

 

As of the date of this proxy statement, we know of no business that will be presented for consideration at the Annual Meeting other than the items referred to above. If any other matter is properly brought before the meeting for action by the stockholders, proxies in the enclosed form returned to the Company or other custodians will be voted in accordance with the recommendation of the Board of Directors or, in the absence of such a recommendation, in accordance with the judgment of the proxy holder.

 

97

 

CONTROL PERSONS

 

The following table sets forth certain information as of the record date, concerning the ownership of the common stock by (a) each person who, to the Company’s knowledge, beneficially owned on that date more than 5% of the outstanding common stock, (b) each of our current directors and executive officers and (c) all of our directors and executive officers as a group.

 

  Number of Shares  Percent of 
Name of Beneficial Owner (a) (b) Beneficially Owned(b)  Common
Stock(b)
 
Estate of Joseph Feldschuh( c)  2,774,455   73.4%
Michael Feldschuh, President and Director(d)  178,807   4.7%
Jonathan Feldschuh, Director(e)  17,241   0.5%
Martin S. Wolpoff, Director(f)  6,000   * 
James A. Lombard, Director(g)  4,500   * 
Bernhard Saxe, Esq., Director(h)  4,200   * 
Edward Feuer, Director (i)  1,333   * 
All directors and officers as a Group (6 persons)  2,986,536   79.1%
  Number of Shares  Percent of 
  Beneficially  Common 
Name of Beneficial Owner (a) (b) Owned(b)  Stock(b) 
Estate of Joseph Feldschuh(c)  2,549,455   63.2%
Michael Feldschuh, President and Director(d)  216,539   5.4%
Jonathan Feldschuh, Director(e)  30,575   *
Robert J. Michel, Chief Financial Officer, Chief Compliance Officer (f)  7,583   * 
Henry Cremisi. MD, Director(g)  23,666   * 
James A. Lombard, Director(h)  6,166   * 
Joy Goudie, Esq., Director(i)  666   * 
Edward Feuer, Director(j)  2,666   * 
All directors and officers as a Group (7 persons) (k)  2,837,316   70.3%

 

*

Indicates less than 1%.

 

(a)Unless otherwise indicated, the address of each person listed is c/o Daxor Corporation, 350 Fifth Avenue, Suite 4740, New York, New York 10118.109 Meco Lane, Oak Ridge, TN 37830.
(b)Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission (the “SEC”)SEC and generally includes voting or investment power with respect to securities. In accordance with SEC rules, shares of common stock issuable upon the exercise of options or warrants which are currently exercisable or which become exercisable within 60 days following March 1, 2018May 17, 2021 are deemed to be beneficially owned by, and outstanding with respect to, the holder of such option or warrant. Except as indicated by footnote, and subject to community property laws where applicable, to the knowledge of the company,Company, each person listed is believed to have sole voting and investment power with respect to all shares of common stock beneficially owned by such person.
(c) 
(c)Includes 2,774,4552,549,455 shares of common stock.
(d) 
(d)Includes 152,806158,206 shares of common stock and 26,00058,333 shares of common stock issuable upon the exercise of options issued under the company’sCompany’s 2004 Stock Option Plan (the “20042004 Option Plan”), and the Company’s 2020 Incentive Compensation Plan (the “2020 Plan”).
(e)Includes 3,908 shares of common stock and 13,33326,667 shares of Common Stock issuable upon the exercise of options issued under the company’s 2004 Stock Option Plan (the “2004 Option Plan”).and the 2020 Plan.
(f)Includes 4,000 shares4,250 of common stock and 2,0003,333 shares of Common Stock issuable upon the exercise of option issued under the 2020 Plan.
(g)Includes 23,666 shares of Common Stock issuable upon the exercise of options issued under the company’s 2004 Stock Option Plan, (the “2004 Option Plan”)..and the 2020 plan.
(g) 
(h)Includes 2,500 shares of common stock and 2,0003,666 shares of common stock issuable upon the exercise of options issued under the 2004 Option Plan, and the 2020 Plan.

(h)

(i)

(j)

 

(i)

Includes 200 shares of common stock and 4,000666 shares of Common Stock issuable upon the exercise of options issued under the company’s 2004 Stock Option Plan (the “2004 Option Plan”).

2020 Plan.

(j)Includes 1,3332,666 shares of Common Stock issuable upon the exercise of options issued under the company’sCompany’s 2004 Stock Option Plan, (the “2004 Option Plan”).

and the 2020 Plan.

(k)See Footnotes (c) through (h)(j).

8

Directors currently serving have options totaling 48,666151,000 shares of common stock exercisable at prices ranging from $7.25$7.75 to $9.46$14.11 per share.

 

  Number of Options 
Name Granted 
Michael Feldschuh  26,00075,000 
Jonathan Feldschuh  13,33340,000 
Bernhard Saxe, Esq.Henry Cremisi MD  4,00025,000 
James A. Lombard  2,0005,000 
Martin S. WolpoffJoy Goudie Esq  2,000 
Edward Feuer  1,3334,000 
   48,666151,000 

 

ADDITIONAL INFORMATION

 

Stockholder Proposals for the 20192022 Annual Meeting

 

Stockholders interested in presenting a proposal for consideration at the Company’s annual meeting of stockholders in 20192022 may do so by following the procedures prescribed in Rule 14a-8 under the Securities Exchange Act of 1934 and the Company’s by-laws. To be eligible for inclusion in the proxy statement, the stockholder proposals must be received by the Company’s President no later than January 14, 2019.February 1, 2022.

 

Stockholders interested in presenting a proposal at the Company’s annual meeting of stockholders outside the procedures prescribed in Rule 14a-8 (namely, a proposal to be presented at the annual meeting of stockholders in 20192022 but not included in the Company’s proxy statement) must be received by the Company’s President no later than January 30, 2019February 1, 2022 to be considered timely. Under the SEC’s proxy voting rules, the Company may exercise discretionary voting authority on stockholder proposals received after such date.

 

Administrator and Principal Underwriters

 

The responsibility of the Board of Directors is to exercise corporate powers and to oversee management of the business of the Company. The officers of the Company are principally responsible for its operations. The Company is not primarily engaged in the business of investing, reinvesting, owning, holding or trading in securities. As such, the Company has no investment advisors,advisor, administrator, principal underwriters, affiliated brokerage, dividend paying agent, non-resident managers, or active portfolio manager. The nature of the instruments in which funds in excess of immediate capital needs are placed are consistent with capital preservation and liquidity. The Company’s Chief Executive Officer, Michael Feldschuh, is primarily responsible for the day-to-day management of any such investments.

Cost and Methods of Solicitation of Proxies

 

Proxy solicitation will be principally by mail but may also be by telephone or personal interview conducted by our officers and regular employees. The cost of solicitation of proxies will be borne by us, including reimbursement of banks, brokerage firms, nominees, fiduciaries and other custodians for reasonable expenses incurred by them in sending the proxy materials to our stockholders.

Householding

We are required to provide an annual report and proxy statement or notice of availability of these materials to all stockholders of record. To reduce the expense of delivering duplicate proxy materials to stockholders who may have more than one account holding but share the same address, we have adopted a procedure approved by the SEC called “householding.” Under this procedure, stockholders who have the same mailing address and last name, and do not participate in electronic delivery of proxy materials, will receive only one copy of the annual report and proxy statement or notice of availability of these materials.

If you are a registered stockholder and would like to have separate copies of the annual report and proxy statement distributed to you in the future, you must submit a request to opt out of householding in writing to Broadridge Financial Solutions, Householding Department, 51 Mercedes Way, Edgewood, New York, 11717, or call Broadridge at (866) 540-7095, and we will cease householding all such documents within 30 days. If you are a beneficial stockholder and would like to have separate copies of the annual report and proxy statement, contact your broker. In addition, stockholders sharing an address receiving multiple copies may also request delivery in the future of a single copy of such documents. Stockholders may notify us of their requests by writing to Broadridge Financial Solutions, Householding Department, 51 Mercedes Way, Edgewood, New York, 11717.

9

Submission of Other Communications to the Board

 

Stockholders and other interested parties may communicate with the Board (or individual directors serving on the board) by sending written communications, addressed to any director or to the Board as a group, to our Chief Financial Officer, John Wilkens,Robert J. Michel, at 350 Fifth Avenue (Empire State Building), Suite 4740, New York, New York 10118,109 Meco Lane, Oak Ridge, TN 37830 who will ensure that the communication (assuming it is properly marked care of the Board or care of a specific director) is delivered to the Board or the specified director, as the case may be. Commercial advertisements or other forms of solicitation will not be forwarded.

 

By Order of the Board of Directors,

ByOrder of the Board of Directors,
/s/ Robert J. Michel
Robert J. Michel
Chief Financial Officer, Chief Compliance Officer and Corporate Secretary
June 1, 2021
New York, NY

 

John Wilkens

Chief Financial Officer

May 22, 2018

New York, NY

1110